Navigation Links
Tolera Therapeutics Files IND Application for TOL101, Appoints O'Toole to Lead Clinical Operations
Date:11/3/2009

a spin-off of the Cleveland Clinic Foundation. Primary investors in the company include Southwest Michigan First Life Sciences Fund, Triathlon Medical Venture Partners, Hopen Therapeutics and the Michigan Economic Development Corporation. Building upon research done at the University of Kentucky and the Cleveland Clinic, Tolera Therapeutics is developing and commercializing therapies for the immune modulation market with the goal of addressing unmet medical needs with safer, more targeted solutions to reduce the risk of serious and toxic side effects often associated with immunotherapy. The company is focusing on commercializing therapeutic monoclonal antibody technology for the transplantation and autoimmune markets. Additional information concerning the company and its technology can be found on its website www.tolera.com.

SOURCE Tolera Therapeutics, Inc.


'/>"/>
SOURCE Tolera Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Phase I Safety and Tolerability Study With EVT 302 Successfully Completed
3. The Immune Tolerance Institute Announces Collaboration with Beckman Coulter Establishing a Multiplatform Immunophenotyping/Immunogenotyping Laboratory
4. Immune Tolerance Institute Appoints Aaron B. Kantor Ph.D. Chief Scientific Officer
5. Hepatitis B Foundation and AAPCHO Sponsor Congressional Briefing on Zero Tolerance for Hepatitis B
6. Laureate Pharma Announces Agreement with Tolera Therapeutics, Inc.
7. Clinical Data Show Long-Acting Human Growth Hormone ARX201 is Safe and Well Tolerated
8. Parion Sciences Announces Initiation of Phase I Clinical Trial to Evaluate Safety and Tolerability of GS9411
9. Phase 3 Data Demonstrate Efficacy and Tolerability of Paliperidone Palmitate, an Investigational Long-Acting Therapy for the Treatment of Schizophrenia
10. First Multiple Dose Clinical Trial of TorreyPines Therapeutics Oral Compound NGX426 Demonstrates Compound Is Safe and Well-Tolerated
11. Tolera Therapeutics Granted Orphan Drug Designation for Organ Transplant Rejection Drug

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)...VIK,Iceland,November24/PRNewswire-FirstCall/--deCO...provalofallofits,"firstday"motionsbytheU.S.Bankrup...urt").deCODElastweekfiledavoluntarypetitionfor,rel...ththe,BankruptcyCourt. , Theordersissuedbythe...itsbusinessduringtheChapter11proceedings.Inparticu...
(Date:11/24/2009)...EO,Calif.,Nov.24/PRNewswire-FirstCall/--NeurogesX,...edondevelopingandcommercializingnovelpainmanagemen...entandChiefExecutiveOfficer,isscheduledtopresentat...heldDecember1-2,2009atTheNewYorkPalaceHotelinNewYo...iefFinancialOfficer,willbeavailabletorespondtoques...
(Date:11/24/2009)...E,Nov.24/PRNewswire/--BlueMarbleEnergyCorp.announc...Authority(OPDA)wererecentlyawarded$2millionbyWashi...ERB)inaprivate/publicpartnershiptoconstructthestat...unty,WA. ,, "Thisinvestmentwillsignificantlyspe...njobstoLincolnCounty,"saidBlueMarbleEnergyCEOKelly...
(Date:11/24/2009)...yefficacyendpointhasbeenmetforpatientswithadvanced...CITY,Nov.24/PRNewswire-FirstCall/-AEternaZentarisI...opharmaceuticalcompanyfocusedonendocrinetherapyand...ase2studywithitstargetedcytotoxicpeptideconjugate,...ecurrentendometrialcancer.Inapersonalizedhealthcar...
Breaking Biology Technology:deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 2deCODE genetics, Inc. Announces Approval of First Day Motions by Bankruptcy Court 3NeurogesX to Present at Piper Jaffray Health Care Conference 2NeurogesX to Present at Piper Jaffray Health Care Conference 3Blue Marble Energy, OPDA Awarded $2M by WA's Community Economic Revitalization Board 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 2AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 3AEterna Zentaris Announces Positive Results for Phase 2 Study with LHRH-Receptor Targeted Cytotoxic Conjugate AEZS-108 in Endometrial Cancer 4
...TON DC, July 29 Athera Biotechnology announced,th...ochemistry) for,Distinguished Abstracts at the ann...ry) meeting in Washinton DC was awarded to Athera,...leagues. The abstract was,one of 26 selected for t...rs will be honored at NACB Award luncheon held at ...
...TON and WELLESLEY, Mass., July 29 Xceed,Molecular...easy-to-use,gene-expression analysis systems, will...nfigured array for use with the company,s Ziplex a...008 AACC/ASCLS Clinical Lab Expo,(booth 2155). The...gton,Convention Center in Washington, DC., "With ...
...e,s a new "gold standard" in the sensitivity of we...h they created the world,s first fully functional ...the University of California (UC) at Berkeley have...hat can function as a scale sensitive enough to me...ettl, a physicist who holds joint appointments wit...
Other Biology Technology:Xceed Molecular to Launch New Inflammation Xpress Chip(TM)for the Ziplex(R) Automated Gene-Expression Analysis System at Clinical Lab Expo 2008, Booth 2155 2Xceed Molecular to Launch New Inflammation Xpress Chip(TM)for the Ziplex(R) Automated Gene-Expression Analysis System at Clinical Lab Expo 2008, Booth 2155 3Golden scales 2Golden scales 3
(Date:11/24/2009)... have crystallised a protein that may help gut bac...ein could be used by probiotic producers to identi...o people. , "Probiotics need to interact with cel... if they attach to surfaces in the gut they are mo...ir activity," says Dr Nathalie Juge from the Insti...
(Date:11/24/2009)...UGE Antarctica has long held secrets of the earth...ently, there has been very little information on t...s of ice for millions of years. Now, a team of res...ve been funded to the tune of $10 million dollars ... to the bottom of things literally. These scienti...
(Date:11/23/2009)..., D.C. The community-associated strain of the dea...istant to most common antibioticsposes a far great...ng its way into hospitals, according to a study in...es . , The new threat is easily picked up in fi...d has increased the overall burden of MRSA within ...
Breaking Biology News(10 mins):A sticky solution for identifying effective probiotics 2LSU gets to the bottom of things -- in Antarctica 2New study finds MRSA on the rise in hospital outpatients 2Echo Therapeutics Announces Positive Results of a Clinical Study Testing Symphony 28TM 29 tCGM System in Patients with Type 1 and Type 2 Diabetes 6409 1Echo Therapeutics Announces Positive Results of a Clinical Study Testing Symphony 28TM 29 tCGM System in Patients with Type 1 and Type 2 Diabetes 6409 2Echo Therapeutics Announces Positive Results of a Clinical Study Testing Symphony 28TM 29 tCGM System in Patients with Type 1 and Type 2 Diabetes 6409 3Echo Therapeutics Announces Positive Results of a Clinical Study Testing Symphony 28TM 29 tCGM System in Patients with Type 1 and Type 2 Diabetes 6409 4Aware Inc Introduces AccuRad ImageShare 28TM 29 Platform at RSNA 2009 6405 1Aware Inc Introduces AccuRad ImageShare 28TM 29 Platform at RSNA 2009 6405 2Aware Inc Introduces AccuRad ImageShare 28TM 29 Platform at RSNA 2009 6405 3Aware Inc Introduces AccuRad ImageShare 28TM 29 Platform at RSNA 2009 6405 4Curemark Opens Patient Enrollment for Autism Treatment at Three More Clinical Trial Sites 6401 1Curemark Opens Patient Enrollment for Autism Treatment at Three More Clinical Trial Sites 6401 2Curemark Opens Patient Enrollment for Autism Treatment at Three More Clinical Trial Sites 6401 3
...ss., March 5 Aware, Inc. (Nasdaq: AWRE ), a lea...cs software, today announced that its Board of Dir...tender offer for up to 3,500,000 shares, or approx...uding the associated preferred share purchase righ... share, for a maximum aggregate purchase price of ...
...., March 11 Lockheed Martin has received a six-ye...nce-based logistics support for the AN/UYQ-70 (Q-7...Q-70 logistics and supply support at over $13 mill...or additional support over the next four years, br...illion. , , This contract follows a recently awar...
..., ILInsects such as honeybees and bumble bees are ...pically moving directly from one flower to an adja... The bees, flight paths have a direct affect on th...flow", fertilization and seed production that resu...he study of gene flow has experienced more attenti...
Other Biology News:Aware, Inc. Commences Dutch Auction Tender Offer 2Aware, Inc. Commences Dutch Auction Tender Offer 3Aware, Inc. Commences Dutch Auction Tender Offer 4U.S. Navy Awards Lockheed Martin Six-year Contract Worth Up to $72 Million for Advanced Display Systems Support 2Flight of the bumble (and honey) bee 2
ANTIGEN-DOWN ASSAY DILUENT from AbD Serotec
Rabbit Anti-HALOPERIDOL Polyclonal Antibody, Unconjugated from AbD Serotec
TMB PLUS DILUENT from AbD Serotec
TMB ONE DILUENT from AbD Serotec
Biology Products: